

**Remarks**

**Election of Claims**

In response to the Office Action mailed August 9, 2007, Applicant elects Group I without traverse, which includes claims 1-46, and 67, drawn to a method of treating a hyperproliferative disorder in a mammal comprising simultaneously or sequentially administering: (i) a therapeutically effective amount of certain antineoplastic agents, and (ii) a therapeutically effective amount of a compound of formula 1.

**Status of Claims**

Upon entry of this amendment, claims 1 to 46 and 67 are currently pending. Claims 47 to 66, and 68 to 96, are cancelled. Applicant respectfully reserves the right to pursue these claims in a continuation application.

**Election of Species**

1) *A single disclosed specifically defined chemical compound species of formula 1.*

Applicant elects the following species of formula 1: 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide. This species is supported, *inter alia*, in the specification at pages 7 to 13. This species is also provided in elected claim 67 above.

2) *A single disclosed specifically defined composition species wherein each active ingredient is specifically provided.*

Applicant elects the composition species defined as Compound X (the mesylate salt of 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide), as presented in Example 6 on page 38 of the specification, where doxirubicin was also co-administered with Compound X.

3) *A single disclosed hyperproliferative disorder species.*

Applicant elects the hyperproliferative disorder of breast cancer, as shown, for example, in the data on pages 37 to 38 of the specification, Example 6.

Extension of Time

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time, for which Applicant hereby petitions, please charge such fees, or credit any overpayment, to Applicant's Deposit Account No. 16-1445.

Respectfully submitted,

Date: February 8, 2008

/Keith D. Hutchinson/

Keith D. Hutchinson  
Attorney For Applicant  
Registration No. 43,687

Pfizer Inc  
Patent Department  
10555 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4608  
Fax: (858) 678-8233